Cipla gets USFDA observations for its Goa facility

Cipla gets USFDA observations for its Goa facility "The United States Food and Drug Administration (USFDA) has classified the inspection conducted at its Goa manufacturing facility from 16-27 September 2019 as Official Action Indicated (OAI).

No comments:

Post a Comment